For the past several years, investors have flocked to biotech on the promise of AI to accelerate drug development, reduce costs and enhance predictability. The math was a no-brainer: Shaving just 10% off the drug development timeline could translate to hundreds of millions saved.

Many of these companies, however, didn’t deliver ROI as quickly as investors expected. Also, 56% of publically traded biotech companies had two or fewer years of cash in 2023, which also diminished investor expectations.

As the president and CEO of a biotech company that incorporates AI into every step of its drug development process, I have seen both the promise—and the limits—of AI. As I think about what separates hype from genuine opportunity in AI-driven drug discovery and development companies, five key elements stand out…

—

For the full Forbes Technology Council article, please visit: AI and Biotech – Forbes Technology Council

 

About BPGbio

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.

Media Contact:

media@bpgbio.com